What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Monday outlined that Weiss executed a sale ...

In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...

Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo in the U.S.

Teva Pharmaceutical Industries Ltd ADR has reached a significant milestone as its stock hit a 52-week high, trading at $25.96. This achievement marks a notable recovery and growth trajectory for the ...

The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...

See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround.

Teva CEO Richard Francis said, "Following the conclusion of the IRA pricing negotiations, we are reiterating our strong ...

Market Domination host Josh Lipton examines some of Wednesday's trending tickers. Apple (AAPL) is reportedly nearing a deal ...

Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently, Teva Pharmaceutical ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid ...